Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Is Geron the Perfect Stock?

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Everyone would love to find the perfect stock. But will you ever really find a stock that gives you everything you could possibly want?

One thing's for sure: If you don't look, you'll never find truly great investments. So let's first take a look at what you'd want to see from a perfect stock, and then decide if Geron (Nasdaq: GERN  ) fits the bill.

The quest for perfection
When you're looking for great stocks, you have to do your due diligence. It's not enough to rely on a single measure, because a stock that looks great based on one factor may turn out to be horrible in other ways. The best stocks, however, excel in many different areas, which all come together to make up a very attractive picture.

Some of the most basic yet important things to look for in a stock are:

  • Growth. Expanding businesses show healthy revenue growth. While past growth is no guarantee that revenue will keep rising, it's certainly a better sign than a stagnant top line.
  • Margins. Higher sales don't mean anything if a company can't turn them into profits. Strong margins ensure a company is able to turn revenue into profit.
  • Balance sheet. Debt-laden companies have banks and bondholders competing with shareholders for management's attention. Companies with strong balance sheets don't have to worry about the distraction of debt.
  • Money-making opportunities. Companies need to be able to turn their resources into profitable business opportunities. Return on equity helps measure how well a company is finding those opportunities.
  • Valuation. You can't afford to pay too much for even the best companies. Earnings multiples are simple, but using normalized figures gives you a sense of how valuation fits into a longer-term context.
  • Dividends. Investors are demanding tangible proof of profits, and there's nothing more tangible than getting a check every three months. Companies with solid dividends and strong commitments to increasing payouts treat shareholders well.

With those factors in mind, let's take a closer look at Geron.


What We Want to See


Pass or Fail?

Growth 5-Year Annual Revenue Growth > 15% (11.8%) fail
  1-Year Revenue Growth > 12% 84.4% pass
Margins Gross Margin > 35% NM fail
  Net Margin > 15% NM fail
Balance Sheet Debt to Equity < 50% 0% pass
  Current Ratio > 1.3 18.03 pass
Opportunities Return on Equity > 15% (41.7%) fail
Valuation Normalized P/E < 20 NM fail
Dividends Current Yield > 2% 0% fail
  5-Year Dividend Growth > 10% 0% fail
  Total Score   3 out of 10

Source: Capital IQ, a division of Standard and Poor's. NM = not meaningful; Geron had negative gross and net profits over the periods measured. Total score = number of passes.

Geron's score of 3 leaves much to be desired. But the company is in a difficult specialty that's charged with political controversy.

Geron is a drug company and as such faces all the normal challenges that drugmakers have. It has no revenue to speak of right now, but it has a pipeline of drugs. For instance, its Imetelstat product to treat lung cancer patients is in phase 2 trials and has promise.

But where Geron focuses its attention is on stem-cell research, which explains the big swings in its stock. At issue is whether federal funding of the research is legal, which has caused huge fights that affect the entire industry. Along with Geron, StemCells (Nasdaq: STEM  ) and Cytori Therapeutics (Nasdaq: CYTX  ) have dealt with volatility as the legal challenges work their way through the courts.

With no sales, this stock is a roller coaster. When the first patient entered a Geron stem-cell clinical trial, shares soared. But earlier this week, when Geron announced a secondary stock offering to raise capital, the stock plunged.

Right now, Geron is a crapshoot. If its pipeline proves promising, then it will soar. Otherwise, the company will fade into obscurity. Despite the charged atmosphere surrounding stem-cell research, Geron remains a company without a blockbuster product, and until it can find one, it will never become the perfect stock.

Keep searching
No stock is a sure thing, but some stocks are a lot closer to perfect than others. By looking for the perfect stock, you'll go a long way toward improving your investing prowess and learning how to separate out the best investments from the rest.

Click here to add Geron to My Watchlist, which can find all of our Foolish analysis on it and all your other stocks.

Fool contributor Dan Caplinger doesn't own shares of the companies mentioned in this article. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool has a disclosure policy.

Read/Post Comments (2) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On December 09, 2010, at 12:10 PM, DRYAU79xYOU wrote:

    Geron / Stem Cells (is/are) the biggest thing since the airplane, nuclear fission, and the PC (to use an analogous example)!!!

    The stock will be at 150+ in 2 years!!!

  • Report this Comment On December 09, 2010, at 1:00 PM, CharlieVegas wrote:

    This was a dumb article; you can’t look at a biotech company with no products for sale and expect it to pass growth and income tests. If you believe in the science (which I do) you would buy Geron for the long term. Geron makes up 50% of my portfolio; they have plenty of cash to make it through FDA trials. When the public starts to see results in humans this stock will be $100+.. I’m looking forward to the phase 2 trials when the dosages are increased in the spinal cord trial. There is a very good chance this company will make paralyzed people walk!!

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1394826, ~/Articles/ArticleHandler.aspx, 10/26/2016 1:51:28 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,198.17 28.90 0.16%
S&P 500 2,138.44 -4.72 -0.22%
NASD 5,253.62 -29.78 -0.56%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/26/2016 1:25 PM
CYTX $1.83 Down -0.01 -0.43%
Cytori Therapeutic… CAPS Rating: *
GERN $2.08 Up +0.01 +0.24%
Geron CAPS Rating: ***
STEM $0.91 Down -0.02 -2.18%
StemCells CAPS Rating: *